Savitskaia K I, Trapeznikova M F, Nekhorosheva A G, Solodilova O E, Nasonov V N, Dutov V V, Kalinin V N, Shanina A G, Rusanova E V
Klin Med (Mosk). 1994;72(2):38-42.
Clinical efficacy of maxaquin versus ciprofloxacin against complicated or/and recurrent urinary infections (62 patients primarily with chronic pyelonephritis with nephrolithiasis) proved higher (92.3% vs 80.0%) in equal microbiological activity (73.2% vs. 73.4%) of the drugs. Maxaquin was less active in enhancing the culture resistance. Both quinolones had no negative effects on the studied systems of the body's antiinfectious resistance and promoted partial correction of dysbiotic manifestations on the colon mucosa. Side effects of both drugs occurred with similar frequency and severity, starting earlier in administration of maxaquin. The authors offer to manage urinary infections in adults effectively with maxaquin in a dose 400 mg once a day and ciprofloxacin in a dose 500 mg twice a day by 7-14-day courses.
针对复杂性或/和复发性泌尿系统感染（62例主要为患有肾结石的慢性肾盂肾炎患者），在两种药物具有同等微生物活性（73.2%对73.4%）的情况下，麦氟沙星对比环丙沙星的临床疗效更高（92.3%对80.0%）。麦氟沙星在增强培养耐药性方面活性较低。两种喹诺酮类药物对人体抗感染抵抗的研究系统均无负面影响，并促进了结肠黏膜生态失调表现的部分纠正。两种药物的副作用发生频率和严重程度相似，麦氟沙星在给药时副作用出现得更早。作者建议，对于成人泌尿系统感染，采用7 - 14天疗程，有效管理方法为每日一次服用400毫克麦氟沙星和每日两次服用500毫克环丙沙星。
